Jazz Pharmaceuticals PLC $JAZZ Holdings Lifted by Bayforest Capital Ltd

Key Points

• Bayforest Capital Ltd increased its holdings in Jazz Pharmaceuticals PLC by 222.6% during Q2, owning 5,791 shares valued at $615,000 after buying an additional 3,996 shares.
• Multiple institutional investors have also boosted their stakes, with total institutional ownership now at 89.14% of the company's stock.
• Jazz Pharmaceuticals reported a quarterly earnings per share of ($8.25), missing estimates, with revenue of $1.05 billion for the quarter, marking a 2.1% year-over-year increase.

Bayforest Capital Ltd increased its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 222.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,791 shares of the specialty pharmaceutical company's stock after buying an additional 3,996 shares during the quarter. Bayforest Capital Ltd's holdings in Jazz Pharmaceuticals were worth $615,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Hurley Capital LLC acquired a new stake in Jazz Pharmaceuticals during the first quarter valued at $25,000. Picton Mahoney Asset Management boosted its position in Jazz Pharmaceuticals by 2,445.5% during the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock valued at $34,000 after purchasing an additional 269 shares during the last quarter. Spire Wealth Management boosted its position in Jazz Pharmaceuticals by 137.6% during the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock valued at $35,000 after purchasing an additional 161 shares during the last quarter. SVB Wealth LLC acquired a new stake in Jazz Pharmaceuticals during the first quarter valued at $36,000. Finally, Geneos Wealth Management Inc. boosted its position in Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company's stock valued at $47,000 after purchasing an additional 137 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, Director Bruce C. Cozadd sold 6,000 shares of the business's stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $128.62, for a total transaction of $771,720.00. Following the completion of the transaction, the director owned 429,973 shares of the company's stock, valued at approximately $55,303,127.26. The trade was a 1.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last ninety days, insiders sold 11,500 shares of company stock worth $1,525,280. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ opened at $133.81 on Wednesday. Jazz Pharmaceuticals PLC has a fifty-two week low of $95.49 and a fifty-two week high of $148.06. The business has a 50-day moving average of $126.67 and a two-hundred day moving average of $115.79. The stock has a market capitalization of $8.12 billion, a P/E ratio of -19.88, a P/E/G ratio of 8.30 and a beta of 0.28. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%.The business had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.05 billion. During the same period in the prior year, the firm posted $5.30 EPS. Jazz Pharmaceuticals's revenue for the quarter was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently issued reports on JAZZ shares. Morgan Stanley lifted their price objective on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the company an "overweight" rating in a research report on Wednesday, September 24th. Royal Bank Of Canada lifted their price objective on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the company an "outperform" rating in a research report on Thursday, August 28th. Needham & Company LLC reissued a "buy" rating and set a $202.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Zacks Research raised Jazz Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Friday, August 15th. Finally, Deutsche Bank Aktiengesellschaft began coverage on Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a "buy" rating and a $152.00 price target for the company. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Jazz Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $178.93.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.